Virtus LifeSci Biotech Products ETF
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more capital invested
Capital invested by funds: $4M [Q2] → $4.81M (+$816K) [Q3]
8% more funds holding
Funds holding: 12 [Q2] → 13 (+1) [Q3]
2.45% more ownership
Funds ownership: 19.42% [Q2] → 21.88% (+2.45%) [Q3]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for BBP.
Financial journalist opinion
Positive
Zacks Investment Research
6 months ago
4 Best-Performing Sector ETFs of June
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Positive
Zacks Investment Research
1 year ago
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Charts implemented using Lightweight Charts™